Novartis’s BYM338

• Government
• Healthcare
• Pharma & Biotech
• Society
• Switzerland

US FDA granted breakthrough therapy designation to Novartis’s BYM338 for sporadic inclusion body myositis

Designation highlights potential of BYM338 to address an unmet medical need in a serious disease If approved, BYM338 has the…